Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$138.95

-1.48 (-1.05%)

, BPMC

Blueprint Medicines

$86.12

5.22 (6.45%)

07:07
05/17/18
05/17
07:07
05/17/18
07:07

Loxo Oncology price target raised to $190 after ASCO abstracts at Stifel

Stifel analyst Stephen Willey said he believes the preliminary efficacy data on Loxo Oncology's (LOXO) LOXO-292 that was reported in abstracts released last night in anticipation of the ASCO meeting should further distance the candidate from other competitive RET inhibitors. The overall response rate, or ORR, of 52% reported for the 46 evaluable patients harboring RET-altered tumors tops the 46% ORR previously-reported for competitor Blueprint Medicines' (BPMC) BLU-667 at AACR, noted Willey. The analyst, who also thinks the disclosure of this data increases visibility for potential strategic buyers who have historically shown a "willingness to pay top-dollar for long-duration targeted oncology agents," increased his price target on Loxo to $190 from $145 and keeps a Buy rating on the shares.

LOXO

Loxo Oncology

$138.95

-1.48 (-1.05%)

BPMC

Blueprint Medicines

$86.12

5.22 (6.45%)

  • 01

    Jun

LOXO Loxo Oncology
$138.95

-1.48 (-1.05%)

04/16/18
MSCO
04/16/18
UPGRADE
MSCO
Overweight
Loxo Oncology upgraded to Overweight from Equal Weight at Morgan Stanley
04/16/18
04/16/18
UPGRADE
Target $170

Overweight
Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130.
04/16/18
STFL
04/16/18
NO CHANGE
STFL
Buy
Blueprint data leaves 'door wide open' for Loxo's LOXO-292, says Stifel
Stifel analyst Stephen Willey noted that Blueprint Medicines (BPMC) reported data from the dose-escalation portion of its Phase 1 trial of BLU-667 at this weekend's AACR meeting. He believes BLU-667 looks like "a sufficiently viable asset for RET-altered tumors," but he also thinks the data has left the competitive window "wide-open" for Loxo Oncology (LOXO) ahead of preliminary LOXO-292 data expected at the ASCO meeting in June. Loxo's data now potentially could shift sentiment on what consensus has been presuming to be a $1B+ opportunity equally-shared between the two companies, Willey tells investors. He maintains a Buy rating on Loxo shares.
05/09/18
JMPS
05/09/18
NO CHANGE
Target $152
JMPS
Outperform
Loxo Oncology price target increased to $152 from $95 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Loxo Oncology to $152 from $95 following an update to his financial model after the company's Q1 earnings report, which he said highlighted its pipeline progress. He maintains an Outperform rating on Loxo shares.
BPMC Blueprint Medicines
$86.12

5.22 (6.45%)

04/16/18
WEDB
04/16/18
NO CHANGE
Target $106
WEDB
Outperform
Blueprint Medicines price target raised to $106 from $98 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Blueprint Medicines to $106 from $98 following encouraging dose escalation data from the Phase 1 ARROW study of RET-inhibitor BLU-667 in patients with RETaltered solid tumors presented at AACR. The analyst reiterates an Outperform rating on the shares.
04/16/18
JMPS
04/16/18
NO CHANGE
Target $109
JMPS
Outperform
Blueprint price target raised to $109 after BLU-667 data at JMP Securities
JMP Securities analyst Konstantinos Aprilakis raised his price target on Blueprint Medicines to $109 from $97 after the company presented data from the Phase I ARROW trial of BLU-667 in patients with solid tumors driven by alterations in RET at the American Association for Cancer Research annual meeting. Among all 53 enrolled patients, an "impressive" 41 patients remained on BLU-667 as of the data cutoff date, Aprilakis noted. He reiterates an Outperform rating on Blueprint shares.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.71

0.33 (0.48%)

12:45
05/25/18
05/25
12:45
05/25/18
12:45
Options
Michael Kors call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 26

    Jun

12:45
05/25/18
05/25
12:45
05/25/18
12:45
General news
Breaking General news story  »

Week of 5/25 Baker-Hughes…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, ACIA

Acacia Communications

$33.68

1.49 (4.63%)

12:39
05/25/18
05/25
12:39
05/25/18
12:39
Periodicals
Trump administration says deal struck on ZTE Corp., NYT reports »

The Trump administration…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$33.68

1.49 (4.63%)

OCLR

Oclaro

$9.13

0.25 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 12

    Jun

  • 10

    Sep

NBR

Nabors Industries

$7.27

-0.54 (-6.91%)

12:35
05/25/18
05/25
12:35
05/25/18
12:35
Options
Nabors Industries put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$100.19

0.01 (0.01%)

12:31
05/25/18
05/25
12:31
05/25/18
12:31
Hot Stocks
PepsiCo confirms agreement to acquire Bare Snacks »

PepsiCo announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$100.29

0.11 (0.11%)

12:29
05/25/18
05/25
12:29
05/25/18
12:29
Periodicals
PepsiCo to acquire baked fruit and veggie snack maker Bare Foods, NYT reports »

PepsiCo will acquire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$55.19

0.41 (0.75%)

12:27
05/25/18
05/25
12:27
05/25/18
12:27
Periodicals
EEOC investigates age discrimination claims against Intel, WSJ reports »

The U.S. Equal Employment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$77.43

-5.52 (-6.65%)

12:20
05/25/18
05/25
12:20
05/25/18
12:20
Options
Notable ratio spread in Ross Stores as shares slump on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.45

-4.52 (-13.71%)

, FL

Foot Locker

$53.39

7.01 (15.11%)

12:18
05/25/18
05/25
12:18
05/25/18
12:18
General news
On The Fly: Top stock stories at midday »

The S&P 500 opened…

GPS

Gap

$28.45

-4.52 (-13.71%)

FL

Foot Locker

$53.39

7.01 (15.11%)

HLF

Herbalife Nutrition

$48.96

-4.89 (-9.08%)

IEP

Icahn Enterprises

$69.33

0.14 (0.20%)

FCAU

Fiat Chrysler

$21.86

-0.4 (-1.80%)

DGX

Quest Diagnostics

$106.60

5.71 (5.66%)

UNH

UnitedHealth

$244.87

2.14 (0.88%)

ROST

Ross Stores

$77.38

-5.57 (-6.71%)

ADSK

Autodesk

$132.89

-5.87 (-4.23%)

AAL

American Airlines

$45.31

1.76 (4.04%)

LUV

Southwest

$53.21

2 (3.91%)

DAL

Delta Air Lines

$55.80

1.39 (2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
05/25/18
05/25
12:17
05/25/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$162.03

-0.01 (-0.01%)

, DIA

Diamonds Fund ETF

$247.61

-0.29 (-0.12%)

12:16
05/25/18
05/25
12:16
05/25/18
12:16
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the week, fund flows…

IWM

iShares Trust Russell 2000 Index Fund

$162.03

-0.01 (-0.01%)

DIA

Diamonds Fund ETF

$247.61

-0.29 (-0.12%)

XLF

Financial Select Sector

$27.87

-0.08 (-0.29%)

XLE

Energy Select Sector SPDR

$74.03

-2.51 (-3.28%)

IVV

iShares Core S&P 500

$274.29

-0.46 (-0.17%)

SPY

SPDR S&P 500 ETF Trust

$272.41

-0.46 (-0.17%)

JNK

SPDR Barclays High Yield Bond

$35.72

-0.03 (-0.08%)

EMB

iShares JP Morgan USD Emerging Markets Bond ETF

$109.63

0.28 (0.26%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.29

0.235 (0.20%)

EFV

iShares MSCI EAFE Value ETF

$54.37

-0.49 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
05/25/18
05/25
12:16
05/25/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$12.00

-1.04 (-7.98%)

12:15
05/25/18
05/25
12:15
05/25/18
12:15
Options
QEP Resources put volume heavy and directionally bearish »

Bearish flow noted in QEP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AIPT

Precision Therapeutics

$1.00

0.01 (1.01%)

, SKLN

Ticker changed to AIPT

$0.00

(0.00%)

12:10
05/25/18
05/25
12:10
05/25/18
12:10
Hot Stocks
Skyline Medical says products approved on DAPA contract »

Skyline Medical sent the…

AIPT

Precision Therapeutics

$1.00

0.01 (1.01%)

SKLN

Ticker changed to AIPT

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$64.84

1.39 (2.19%)

12:05
05/25/18
05/25
12:05
05/25/18
12:05
Options
Kellogg call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

12:05
05/25/18
05/25
12:05
05/25/18
12:05
General news
Treasury Option Action: some bullish positioning »

Treasury Option Action:…

GIFI

Gulf Island Fabrication

$10.40

-0.05 (-0.48%)

11:56
05/25/18
05/25
11:56
05/25/18
11:56
Hot Stocks
Gulf Island Fabrication awarded 3300HP towboat newbuild project with option »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.96

0.86 (0.84%)

, TWX

Time Warner

$94.04

-0.22 (-0.23%)

11:54
05/25/18
05/25
11:54
05/25/18
11:54
Hot Stocks
Box Office Battle: 'Solo' looking to shoot first, take out 'Deadpool 2' »

Disney's (DIS) Han…

DIS

Disney

$102.96

0.86 (0.84%)

TWX

Time Warner

$94.04

-0.22 (-0.23%)

VIAB

Viacom

$27.69

0.4 (1.47%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$24.50

1.17 (5.02%)

LGF.B

Lionsgate

$23.05

1 (4.54%)

SNE

Sony

$46.56

0.11 (0.24%)

VIA

Viacom

$32.45

0.6 (1.88%)

FOX

21st Century Fox

$38.81

0.31 (0.81%)

FOXA

21st Century Fox

$39.25

0.32 (0.82%)

CMCSA

Comcast

$31.99

0.35 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$80.14

-0.44 (-0.55%)

11:53
05/25/18
05/25
11:53
05/25/18
11:53
Conference/Events
Nektar to hold 2018 ASCO Investor Event »

In conjunction with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 12

    Jun

CELG

Celgene

$79.23

-0.25 (-0.31%)

11:50
05/25/18
05/25
11:50
05/25/18
11:50
Conference/Events
Celgene to hold analyst and investor event from ASCO Annual Meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 02

    Jun

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

NKE

Nike

$72.43

0.29 (0.40%)

11:50
05/25/18
05/25
11:50
05/25/18
11:50
Options
Notable spread in Nike as shares reach new highs »

Notable spread in Nike as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AFSI

AmTrust

$13.76

0.035 (0.26%)

11:49
05/25/18
05/25
11:49
05/25/18
11:49
Hot Stocks
Icahn says ISS recommends shareholders vote against AmTrust going-private deal »

Carl Icahn issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRLCY

L'Oreal

$0.00

(0.00%)

11:46
05/25/18
05/25
11:46
05/25/18
11:46
Hot Stocks
L'Oreal to acquire Pulp Riot Hair Color »

L'Oreal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$38.70

2.72 (7.56%)

11:45
05/25/18
05/25
11:45
05/25/18
11:45
Options
Roku Inc (Class A Stock) call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
05/25/18
05/25
11:45
05/25/18
11:45
Conference/Events
Barclays biopharmaceutical analyst to hold an analyst/industry conference call »

U.S. Biopharmaceuticals…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.